Journal of Clinical Oncology (JCO) Podcast

This Podcast reviews the design and results of the present study by Kennecke et al. and provides perspective regarding the clinical significance of these findings.

This podcast reviews the rationale behind evaluation of metformin as a potential anti-cancer agent in breast cancer and describes the findings of a recent window of opportunity trial looking at the impact of metformin upon proliferative indices in women with early breast cancer.

This podcast reviews the results of the FACT trial in the context of other ongoing and proposed studies of endocrine therapy combinations.

This podcast describes a phase 2 trial brentuximab vedotin in patients with Hodgkin lymphoma that has recurred after autologous hematopoietic stem cell transplantation. The podcast discusses the rationale for the trial, response to therapy, and associated toxicities. Future application of brentuximab vedotin to CD30+ malignancies is considered as well.

In this study, the implications of long term follow up of the German Rectal Study on clinical practice and future trial design will be discussed.

Carboplatin-Gemcitabine-Bevacizumab represents an additional regimen to consider for management of recurrent platinum sensitive epithelial ovarian cancer, although it raises several questions regarding the role of bevacizumab in this disease setting.

This podcast discusses adjuvant therapy in elderly NSCLC patients.

The podcast highlights recent JCO articles that underscore the need for improved assessment and management of cancer and treatment-related symptoms.

The CHER-LOB trial is one of several that has demonstrated that adding lapatinib to trastuzumab and chemotherapy improves on the rates of complete pathological response among women receiving neoadjuvant therapy for HER2 positive breast cancer. Because the relationship between pCR and long-term outcomes remains ambiguous, this regimen is not recommended for ordinary use. However, these findings are...

A reflection on the problems clinicians face when making a decision on how best to advise patients regarding management of early clear cell carcinoma of the ovary.

This podcast provides observations and commentary on the JCO article "High risk of symptomatic cardiac events in childhood cancer survivors.

This podcast reviews a negative phase III clinical trial of cetuximab combined with chemotherapy in first-line metastatic colorectal cancer and focuses on the interaction of targeted therapy combined with chemotherapy.

This podcast partitions patients with early melanoma into those with very favorable features and compares them to those with a higher risk for dying of metastatic melanoma.

Incorporating the information form Dr Marconi's systematic review on the question "Does sedation at the end of life hasten death", I will provide useful guidance regarding how to discuss this issues with patients and their families.

This podcast describes the results from a subgroup of 732 women in the NSABP B-24 trial for the treatment of DCIS, where ER status was available, and describes how this can be used as a predictive test for response to adjuvant tamoxifen.

In this podcast, I will review a JCO article showing that the publication of CALGB C9343 trial results had little influence in practice patterns in the United States. I will discuss possible study-specific reasons for the lack in change of practice and explore the author's implication that practitioners are more apt to adopt trials that add technologies and/or treatments compared to those that wit...

This podcast will discuss the current role of characterizing KRAS and BRAF in the management of colorectal cancer as well as a manuscript by Popovici and colleagues entitled "Identification of a poor prognosis BRAF-mutant-like population of colon cancer patients". In this manuscript, a molecular signature that characterizes a subgroup of colorectal cancers that behave like BRAF mutant tumors but d...

Patients with epidermal growth factor receptor (EGFR) gene mutations should receive EGFR tyrosine kinase inhibitors as 1st line therapy because they produce higher response rates, long progression free survival, reduced toxicity, improved symptom control and convenience of oral administration compared to chemotherapy doublets.

This JCO Podcast provides observations and commentary on the JCO article, "Randomized Phase III study comparing Paclitaxel Cisplatin Gemcitabine and Gemcitabine Cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC 30987 Intergroup Study" by Joaquim Bellmunt et al. It provides my perspective that considers both statistical metrics and cli...

The management of patients with early stage Hodgkin lymphoma with unfavorable characteristics remains a topic for study.

This podcast reports on a phase I/II trial investigating novel anti-CD22, moxetumomab pasudotox, in the treatment of patients with refractory hairy cell leukemia, which demonstrated responses in the majority of patients at all dose levels.

When dose dense treatment was first described we were greatly enthusiastic for all women with breast cancer. As the experience has matured we now realize that the benefit is confined to women with ER negative cancers. We think it is time to question our use of CSFs and dose dense treatment in ER+ women based on 2 large trials and a conclusive meta-analysis.

This podcast summarizes and discusses the outcome results of the GOG Lap2 trial which shows safety and clinical benefits of laparoscopy as compared to laparotomy for surgical staging and treatment of uterine cancer.

This is a commentary on a report from the EBMT demonstrating a higher relapse rate after allogeneic transplantation in AML patients with FLT3 ITD mutations.

Long-term follow-up of efficacy and toxicity outcomes from the IES study of adjuvant aromatase inhibitor therapy in postmenopausal estrogen receptor positive breast cancer